Canopy Growth Corp. (CGC) is in the news today. They reported their fiscal Q4 results and also recorded impairment and restructuring charges of $743 million, the majority of which are non-cash charges. I will leave the fundamental analysis and numbers crunching to others but use this time to check on the charts and indicators.
More from Investing
No news can explain the action -- whether the bears believe it or not.
The last few post-earnings beat downs were greeted with optimism once traders got over the initial disappointment.
Forte's sole clinic candidate is FB-401 for the treatment of atopic dermatitis, which is the scientific name for eczema.